Yisheng Granted US Orphan Drug Designation for Rabies Vaccine

Yisheng Biopharma of Beijing was granted US Orphan Drug designation for its lead vaccine candidate, a novel PIKA rabies vaccine. The vaccine, which uses Yisheng's proprietary toll-like receptor-3 (TLR-3) activation technology, is currently in Phase II trials. The PIKA vaccine requires only three injections in seven days, as opposed to the usual regimen of five shots over 28 days. In the Phase I trial, it created a faster response to rabies infection. Three months ago, Yisheng was granted US Orphan Drug designation for its livery cancer immunotherapy. More details.... Share this with colleagues: // //